文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

十年群体水平基因组监测揭示大肠埃希菌和肺炎克雷伯菌血清型以指导疫苗开发

Ten Years of Population-Level Genomic Escherichia coli and Klebsiella pneumoniae Serotype Surveillance Informs Vaccine Development for Invasive Infections.
PubMed 文献 · Clin Infect Dis · 2021-01-01

该研究对英国牛津郡2008至2018年血流感染的大肠埃希菌和肺炎克雷伯菌进行无选择群体水平基因组监测,并分析全球公开测序数据。发现四种常见大肠埃希菌O抗原及四种肺炎克雷伯菌O抗原覆盖率随时间增加,且在多重耐药和ESBL耐药菌株中占比较高;针对O抗原的疫苗可能有助于降低相关血流感染的疾病负担和耐药性。

要点

  • 这四种O型覆盖牛津郡616/1434多重耐药和173/256 ESBL耐药大肠埃希菌。

核心结论

  • 针对O抗原的疫苗可能有助于降低大肠埃希菌和肺炎克雷伯菌血流感染相关的发病率、死亡率和抗菌药物耐药性。

研究设计与样本

  • 对英国牛津郡2008至2018年血流感染的大肠埃希菌和肺炎克雷伯菌进行无选择群体水平基因组监测,并补充分析全球公开测序数据(n=3678)。

主要发现

  • 测序3478株大肠埃希菌(3278株通过质控)和556株肺炎克雷伯菌(535株K抗原和549株O抗原通过质控)。
  • 大肠埃希菌四种最常见O抗原(O1/O2/O6/O25)见于1499/3278株,发病率逐年增加(IRR=1.14,95%CI 1.11-1.16)。
  • 这些O型占牛津郡616/1434多重耐药和173/256 ESBL耐药大肠埃希菌,但仅占所有研究中19/90碳青霉烯耐药菌株。
  • 肺炎克雷伯菌最常见O抗原(O2v2/O1v1/O3b/O1v2)占410/549株,发病率逐年增加(IRR=1.09,95%CI 1.05-1.12)。
  • 这些O型占牛津郡122/148多重耐药和106/123 ESBL肺炎克雷伯菌,以及所有研究中557/734碳青霉烯耐药菌株。

关键数值与推荐

  • 大肠埃希菌中,ExPEC4V和ExPEC10V疫苗基于血清分型分别覆盖牛津郡46%和72%的分离株,以及47%和71%的多重耐药分离株。

临床怎么用

  • O抗原靶向疫苗可能用于减少大肠埃希菌和肺炎克雷伯菌血流感染相关的发病率、死亡率和抗菌药物耐药性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The incidence of bloodstream infections (BSIs) caused by Escherichia coli and Klebsiella pneumoniae is increasing, with substantial associated morbidity, mortality, and antimicrobial resistance. Unbiased serotyping studies to guide vaccine target selection are limited. METHODS: We conducted unselected, population-level genomic surveillance of bloodstream E. coli and Klebsiella pneumoniae isolates from 2008 to 2018 in Oxfordshire, United Kingdom. We supplemented this with an analysis of publicly available global sequencing data (n = 3678). RESULTS: We sequenced 3478 E. coli isolates (3278 passed quality control) and 556 K. pneumoniae isolates (535 [K-antigen] and 549 [O-antigen] passed quality control). The 4 most common E. coli O-antigens (O1/O2/O6/O25) were identified in 1499/3278 isolates; the incidence of these O-types increased over time (incidence rate ratio per year [IRRy] = 1.14, 95% confidence interval [CI]: 1.11-1.16). These O-types accounted for 616/1434 multidrug-resistant (MDR) and 173/256 extended-spectrum beta-lactamase (ESBL)-resistant isolates in Oxfordshire but only 19/90 carbapenem-resistant isolates across all studies. For Klebsiella pneumoniae, the most common O-antigens (O2v2/O1v1/O3b/O1v2) accounted for 410/549 isolates; the incidence of BSIs caused by these also increased annually (IRRy = 1.09; 95% CI: 1.05-1.12). These O-types accounted for 122/148 MDR and 106/123 ESBL isolates in Oxfordshire and 557/734 carbapenem-resistant isolates across all studies. Conversely we observed substantial capsular antigen diversity. Analysis of 3678 isolates from global studies demonstrated the generalizability of these findings. For E. coli, based on serotyping, the ExPEC4V and ExPEC10V vaccines under investigation would cover 46% and 72% of Oxfordshire isolates respectively, and 47% and 71% of MDR isolates. CONCLUSIONS: O-antigen targeted vaccines may be useful in reducing the morbidity, mortality, and antimicrobial resistance associated with E. coli and K. pneumoniae BSIs.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Lipworth S, Vihta KD, Chau KK, et al. Ten Years of Population-Level Genomic Escherichia coli and Klebsiella pneumoniae Serotype Surveillance Informs Vaccine Development for Invasive Infections. Clin Infect Dis. 2021. PMID: 33411882. doi:10.1093/cid/ciab006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。